These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 16961463

  • 1. Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases.
    Chase A, Cross NC.
    Clin Sci (Lond); 2006 Oct; 111(4):233-49. PubMed ID: 16961463
    [Abstract] [Full Text] [Related]

  • 2. Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies.
    Chalandon Y, Schwaller J.
    Haematologica; 2005 Jul; 90(7):949-68. PubMed ID: 15996933
    [Abstract] [Full Text] [Related]

  • 3. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
    Jabbour E, Cortes J, Kantarjian H.
    Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
    [Abstract] [Full Text] [Related]

  • 4. Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.
    Zhu N, Xiao H, Wang LM, Fu S, Zhao C, Huang H.
    Future Oncol; 2015 Nov; 11(4):659-73. PubMed ID: 25686120
    [Abstract] [Full Text] [Related]

  • 5. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
    Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, Soulieres D, Dirnhofer S, Harlow A, Town A, McKinley A, Supple SG, Seymour J, Di Scala L, van Oosterom A, Herrmann R, Nikolova Z, McArthur AG, Imatinib Target Exploration Consortium Study B2225.
    Clin Cancer Res; 2008 May 01; 14(9):2717-25. PubMed ID: 18451237
    [Abstract] [Full Text] [Related]

  • 6. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
    Ernst T, Erben P, Müller MC, Paschka P, Schenk T, Hoffmann J, Kreil S, La Rosée P, Hehlmann R, Hochhaus A.
    Haematologica; 2008 Feb 01; 93(2):186-92. PubMed ID: 18223278
    [Abstract] [Full Text] [Related]

  • 7. Flying under the radar: the new wave of BCR-ABL inhibitors.
    Quintás-Cardama A, Kantarjian H, Cortes J.
    Nat Rev Drug Discov; 2007 Oct 01; 6(10):834-48. PubMed ID: 17853901
    [Abstract] [Full Text] [Related]

  • 8. Applying the discovery of the Philadelphia chromosome.
    Sherbenou DW, Druker BJ.
    J Clin Invest; 2007 Aug 01; 117(8):2067-74. PubMed ID: 17671641
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Role of tyrosine kinase inhibitors in cancer therapy.
    Arora A, Scholar EM.
    J Pharmacol Exp Ther; 2005 Dec 01; 315(3):971-9. PubMed ID: 16002463
    [Abstract] [Full Text] [Related]

  • 13. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J.
    Clin Cancer Res; 2007 Feb 15; 13(4):1089-97. PubMed ID: 17317816
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.
    Oncogene; 2008 Aug 07; 27(34):4678-89. PubMed ID: 18427551
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
    Tanaka R, Kimura S.
    Expert Rev Anticancer Ther; 2008 Sep 07; 8(9):1387-98. PubMed ID: 18759691
    [Abstract] [Full Text] [Related]

  • 20. Roots of imatinib resistance: a question of self-renewal?
    Burchert A.
    Drug Resist Updat; 2007 Sep 07; 10(4-5):152-61. PubMed ID: 17683977
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.